The subgroup analyses results were consistent. Irrespective of PPI prescription days, PPI use was associated with higher CRS occurrence (aOR 1.46 95% CI 1.26–1.69, P < 0.001) in the 30–89-day PPI user group. The rate of CRS was higher in current (33.8% ) and past (26.3% ) PPI users than PPI non-users (19.1%, P < 0.001). There was a difference in PPI prescription history and prescription duration between the CRS and control groups. Subgroup analyses were performed according to age and sex. Conditional logistic regression analyzed the crude and adjusted odds ratios (ORs) with 95% confidence intervals (CI). ICD-10 codes defined CRS, and claim codes defined previous PPI use.
We analyzed PPI use by patients with and without CRS. Patients with CRS ( n = 7194) and control participants ( n = 28,776) were matched by random order at a 1:4 ratio for age, sex, income group, region of residence, and index date. The Korea National Health Insurance Service-National Sample Cohort was assessed from 2002 to 2013.
This study aimed to evaluate the relationship between chronic rhinosinusitis (CRS) and proton pump inhibitor (PPI) use in a Korean population.
0 kommentar(er)
